CVRX
insider transactionsCVRx, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+9.0K
47.4K buy · 38.4K sell
Net value · 365d
-$50.2K
$300.4K in · $350.6K out
Sentiment · 365d
Net buying
46% buying · 54% selling
Open-market trades · 365d
9
47.4K buy · 38.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
11.2K sh
Own New
-
Grant·A
Director
$0
8.7K sh
Own New
-
Grant·A
Director
$0
11.2K sh
Own New
-
Grant·A
Director
$0
8.7K sh
Own New
-
Grant·A
Director
$0
11.2K sh
Own New
-
Grant·A
Director
$0
8.7K sh
Own +154%
-
Grant·A
Director
$0
11.2K sh
Own New
-
Grant·A
Director
$0
8.7K sh
Own New
-
Grant·A
Director
$0
11.2K sh
Own New
-
Grant·A
Director
$0
8.7K sh
Own +28%
-
Grant·A
Director
$0
36.3K sh
Own New
-
Grant·A
Director
$0
29.0K sh
Own New
-
Grant·A
Director
$0
11.2K sh
Own New
-
Grant·A
Director
$0
8.7K sh
Own New
-
Sell·S
Chief Revenue Officer · 10b5-1
$31.3K
4.0K sh · $7.90
Own -4%
-
Sell·S
CHIEF MKTG & STRAT OFFICER · 10b5-1
$10.1K
1.3K sh · $7.90
Own -2%
-
Sell·S
Jared Oasheim KEY
CHIEF FINANCIAL OFFICER · 10b5-1
$13.8K
1.7K sh · $7.90
Own -2%
-
Sell·S
Kevin Hykes KEY
PRES & CEO · 10b5-1
$61.3K
7.8K sh · $7.90
Own -3%
-
Grant·A
CHIEF HUMAN RESOURCES OFFICER
$0
154.5K sh
Own New
-
Grant·A
CHIEF HUMAN RESOURCES OFFICER
$0
34.0K sh
Own New
-
Sell·S
Chief Medical Officer · 10b5-1
$10.0K
1.3K sh · $7.90
Own -2%
-
Grant·A
Chief Revenue Officer · 10b5-1
$0
52.0K sh
Own New
-
Grant·A
Chief Revenue Officer · 10b5-1
$0
35.0K sh
Own +64%
-
Grant·A
CHIEF MKTG & STRAT OFFICER · 10b5-1
$0
67.0K sh
Own New
-
Grant·A
CHIEF MKTG & STRAT OFFICER · 10b5-1
$0
45.0K sh
Own +267%
-
Grant·A
Jared Oasheim KEY
CHIEF FINANCIAL OFFICER · 10b5-1
$0
91.0K sh
Own New
-
Grant·A
Jared Oasheim KEY
CHIEF FINANCIAL OFFICER · 10b5-1
$0
61.0K sh
Own +163%
-
Grant·A
Kevin Hykes KEY
PRES & CEO · 10b5-1
$0
238.0K sh
Own New
-
Grant·A
Kevin Hykes KEY
PRES & CEO · 10b5-1
$0
159.0K sh
Own +120%
-
Grant·A
CHIEF OPERATING OFFICER
$0
23.0K sh
Own New
-
Grant·A
CHIEF OPERATING OFFICER
$0
15.0K sh
Own +90%
-
Grant·A
Chief Medical Officer · 10b5-1
$0
62.0K sh
Own New
-
Grant·A
Chief Medical Officer · 10b5-1
$0
41.0K sh
Own +188%
-
Buy·P
Director
$297.6K
46.8K sh · $6.36
Own +5%
-
Buy·P
Director
$2.8K
600 sh · $4.64
Own +12%
-
Sell·S
$63.6K
6.3K sh · $10.03
Own -0%
-
Sell·S
$160.5K
16.0K sh · $10.03
Own -0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Martha Shadan | Grant A | 11.2K | $0 |
| Jun 1, 2026 | Martha Shadan | Grant A | 8.7K | $0 |
| Jun 1, 2026 | Mitch C. Hill, | Grant A | 11.2K | $0 |
| Jun 1, 2026 | Mitch C. Hill, | Grant A | 8.7K | $0 |
| Jun 1, 2026 | Mudit K. Jain | Grant A | 11.2K | $0 |
| Jun 1, 2026 | Mudit K. Jain | Grant A | 8.7K | $0 |
| Jun 1, 2026 | Kirk G. Nielsen | Grant A | 11.2K | $0 |
| Jun 1, 2026 | Kirk G. Nielsen | Grant A | 8.7K | $0 |
| Jun 1, 2026 | Joseph P Slattery | Grant A | 11.2K | $0 |
| Jun 1, 2026 | Joseph P Slattery | Grant A | 8.7K | $0 |
| Jun 1, 2026 | DALE MICHAEL D | Grant A | 36.3K | $0 |
| Jun 1, 2026 | DALE MICHAEL D | Grant A | 29.0K | $0 |
| Jun 1, 2026 | Kevin J. Ballinger | Grant A | 11.2K | $0 |
| Jun 1, 2026 | Kevin J. Ballinger | Grant A | 8.7K | $0 |
| Mar 2, 2026 | Robert Allen John 10b5-1 | Sell S | 4.0K | $31.3K |
| Mar 2, 2026 | Paul Verrastro 10b5-1 | Sell S | 1.3K | $10.1K |
| Mar 2, 2026 | Jared Oasheim KEY 10b5-1 | Sell S | 1.7K | $13.8K |
| Mar 2, 2026 | Kevin Hykes KEY 10b5-1 | Sell S | 7.8K | $61.3K |
| Mar 2, 2026 | Gregory Morrison | Grant A | 154.5K | $0 |
| Mar 2, 2026 | Gregory Morrison | Grant A | 34.0K | $0 |
| Mar 2, 2026 | Philip B. Adamson 10b5-1 | Sell S | 1.3K | $10.0K |
| Feb 27, 2026 | Robert Allen John 10b5-1 | Grant A | 52.0K | $0 |
| Feb 27, 2026 | Robert Allen John 10b5-1 | Grant A | 35.0K | $0 |
| Feb 27, 2026 | Paul Verrastro 10b5-1 | Grant A | 67.0K | $0 |
| Feb 27, 2026 | Paul Verrastro 10b5-1 | Grant A | 45.0K | $0 |
| Feb 27, 2026 | Jared Oasheim KEY 10b5-1 | Grant A | 91.0K | $0 |
| Feb 27, 2026 | Jared Oasheim KEY 10b5-1 | Grant A | 61.0K | $0 |
| Feb 27, 2026 | Kevin Hykes KEY 10b5-1 | Grant A | 238.0K | $0 |
| Feb 27, 2026 | Kevin Hykes KEY 10b5-1 | Grant A | 159.0K | $0 |
| Feb 27, 2026 | Brent Binkowski | Grant A | 23.0K | $0 |
| Feb 27, 2026 | Brent Binkowski | Grant A | 15.0K | $0 |
| Feb 27, 2026 | Philip B. Adamson 10b5-1 | Grant A | 62.0K | $0 |
| Feb 27, 2026 | Philip B. Adamson 10b5-1 | Grant A | 41.0K | $0 |
| Feb 20, 2026 | Mudit K. Jain | Buy P | 46.8K | $297.6K |
| Feb 18, 2026 | Mudit K. Jain | Buy P | 600 | $2.8K |
| Nov 26, 2025 | JOHNSON & JOHNSON / Johnson & Johnson Innovation - JJDC, Inc. | Sell S | 6.3K | $63.6K |
| Nov 25, 2025 | JOHNSON & JOHNSON / Johnson & Johnson Innovation - JJDC, Inc. | Sell S | 16.0K | $160.5K |
About CVRX insider trading
This page tracks insider transactions for CVRx, Inc. (CVRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.